AG
ONC

Artal Group’s BeOne Medicines Ltd ONC Stock Holding History

Artal Group’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100,000
Closed -$22M – 145
2022
Q4 		$22M Buy
100,000
+50,000
+100% +$9.17M 1.23% 26
2022
Q3 		$6.74M Buy
+50,000
New +$8.59M 0.29% 53
2019
Q1 		– Sell
-200,000
Closed -$28.1M – 118
2018
Q4 		$28.1M Buy
+200,000
New +$26.5M 1.04% 22

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Artal Group's ONC Position: Q3 2024 in Review

Artal Group sold out of BeOne Medicines Ltd (ONC) in Q3 2024, closing a stake of 303,369 shares — an estimated $43.3M sold.

Artal Group first reported a position in ONC in Q4 2016 and held it in 31 quarters. The position peaked at $296M in Q1 2021. 228 funds tracked by Wall St. Rank hold ONC as of Q3 2024.

  • Artal Group reported no remaining BeOne Medicines Ltd position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 303,369 BeOne Medicines Ltd shares in Q3 2024, an estimated $43.3M.
  • Artal Group first reported a position in BeOne Medicines Ltd in Q4 2016 and held it in 31 quarters.
  • Artal Group's BeOne Medicines Ltd position peaked at $296M in Q1 2021.
  • 228 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.